NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

CAMP

CAMP4 Therapeutics Corp

Jul 11 • 04:00PM ET

1.50

Dollar change -0.04
Percentage change -2.60	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI VXF VTWO IWC VTWG IWM VTWV IWO IWN

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	86.90%	Shs Outstand	20.16M	Perf Week	4.90%
Market Cap	30.24M	Forward P/E	-	EPS next Y	-2.21	Insider Trans	0.00%	Shs Float	2.64M	Perf Month	-14.77%
Enterprise Value	-11.12M	PEG	-	EPS next Q	-0.67	Inst Own	12.91%	Short Float	12.70%	Perf Quarter	-29.91%
Income	-	P/S	-	EPS this Y	77.50%	Inst Trans	-5.19%	Short Ratio	1.02	Perf Half Y	-67.25%
Sales	-	P/B	0.59	EPS next Y	11.14%	ROA	-	Short Interest	0.34M	Perf YTD	-71.26%
Book/sh	2.56	P/C	0.61	EPS next 5Y	44.12%	ROE	-	52W High	12.30 -87.80%	Perf Year	-
Cash/sh	2.45	P/FCF	-	EPS past 3/5Y	-6.52% -	ROIC	-	52W Low	1.30 14.94%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.52% 10.42%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	0.16	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.02	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	43.83	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	8.02	EPS Q/Q	-6.34%	SMA20	1.63%	Beta	-	Target Price	15.25
Payout	-	Debt/Eq	0.15	Sales Q/Q	145.14%	SMA50	-16.29%	Rel Volume	0.19	Prev Close	1.54
Employees	55	LT Debt/Eq	0.09	Earnings	May 13 AMC	SMA200	-68.49%	Avg Volume	329.29K	Price	1.50
IPO	Oct 11, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	10.64% 303.92%	Trades		Volume	61,664	Change	-2.60%

Date	Action	Analyst	Rating Change	Price Target Change
May-27-25	Initiated	Wedbush	Outperform	$8
Nov-05-24	Initiated	William Blair	Outperform
Nov-05-24	Initiated	Piper Sandler	Overweight	$18
Nov-05-24	Initiated	JP Morgan	Overweight	$23

Jun-30-25 08:00AM	Sequans Appoints Jason W. Cohenour to Board of Directors (Newsfile)
May-16-25 06:00AM	CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire) +9.52%
May-13-25 04:05PM	CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire) -7.92%
Apr-28-25 04:30PM	CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire) -10.00% -5.15%
Apr-05-25 11:00AM	Markets Watch Out For Core CPI With Big Banks Set To Report Earnings (Seeking Alpha)
04:05PM	Loading…
Mar-27-25 04:05PM	CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -10.16%
Mar-18-25 08:00AM	CAMP4 Appoints Multiple Industry Veterans to its Board of Directors (GlobeNewswire)
Mar-04-25 05:24AM	CAMP4 Therapeutics Corporation (CAMP): Among Penny Stocks with Insider Buying in 2025 (Insider Monkey) -5.27%
Feb-06-25 08:00AM	CAMP4 to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.95%
Jan-13-25 08:00AM	CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-07-25 04:05PM	CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones (GlobeNewswire)
Dec-10-24 08:00AM	CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors (GlobeNewswire) -8.08%
Dec-02-24 08:00AM	CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire) +5.85%
Nov-21-24 04:05PM	CAMP4 Reports Third Quarter 2024 Financial Results (GlobeNewswire) +8.44% -6.40%
Oct-10-24 07:07PM	CAMP4 Announces Pricing of Initial Public Offering (GlobeNewswire)

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Northpond Ventures II GP, LLC	10% Owner	Oct 15 '24	Buy	11.00	763,636	8,399,996	763,636	Oct 17 06:34 PM
AH Equity Partners Bio I, L.L.	10% Owner	Oct 15 '24	Buy	11.00	727,272	7,999,992	1,579,885	Oct 17 05:05 PM
Enavate Sciences GP, LLC	10% Owner	Oct 15 '24	Buy	11.00	1,363,636	14,999,996	3,785,802	Oct 17 04:15 PM
Polaris Management Co. VII, L.	10% Owner	Oct 15 '24	Buy	11.00	909,090	9,999,990	909,090	Oct 15 06:00 PM
5AM Partners VI, LLC	10% Owner	Oct 15 '24	Buy	11.00	909,090	9,999,990	2,625,145	Oct 15 05:56 PM
Nashat Amir	Director	Oct 15 '24	Buy	11.00	909,090	9,999,990	909,090	Oct 15 05:49 PM
Schwab Andrew J.	Director	Oct 15 '24	Buy	11.00	909,090	9,999,990	2,625,145	Oct 15 05:48 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CAMP

CAMP4 Therapeutics Corp

Upgrade your FINVIZ experience